24.07.07 (ÀÏ) 01:57

Dailypharm

X
"³ëº§»ó°ú L-¾Æ¸£±â´ÑÀÇ ÀÓ»óÀû °¡Ä¡"
µ¥Àϸ®ÆÊ 2017-11-29 12:14:54
"³ëº§»ó°ú L-¾Æ¸£±â´ÑÀÇ ÀÓ»óÀû °¡Ä¡"
µ¥Àϸ®ÆÊ 2017-11-29 12:14:54
ÀǾàÇ° ¼ººÐ ¸®ºä | ȲÀº°æ ¾à»ç(ºÎ»ê ¿À°Å¸®¾à±¹)



L-¾Æ½ºÆĸ£Æ®»ê-L-¾Æ¸£±â´Ñ°ú ³ëº§»óÀº ¾î¶² »ó°ü°ü°è°¡ ÀÖÀ»±î? ÃÖ±Ù ÀÌ °°Àº ¼ººÐÀ» ÇÔÀ¯ÇÑ ÀϹÝÀǾàÇ°, ¶ó¶ó¿Ã¶ó¶ó´Â Á¦Ç°ÀÌ ¾à±¹ Áø¿­´ë¿¡ ¿Ã¶ú´Ù.

1998³â ·Î¹öÆ® F ÆÛÄ¡°íÆ®¿Í ·çÀ̽º À̱׳ª·Î¿Í Æ丮µå ¹Â¶óµå°¡ ³ëº§ »ý¸®ÇлóÀ» °øµ¿ ¼ö»óÇß´Ù. ½ÉÇ÷°ü°è ½ÅÈ£Àü´Þ ºÐÀÚ·Î NO (nitric oxide, »êÈ­Áú¼Ò)¸¦ ¹ß°ßÇÑ °ø·Î¸¦ ÀÎ Á¤ ¹ÞÀº °ÍÀÌ´Ù. 20³â¼¼¿ù À̵éÀº Ç÷°ü±ÙÀ°¼¼Æ÷¸¦ À̿ϽÃÅ°´Â Ç÷°ü³»ÇǼ¼Æ÷¿¡¼­ »ý¼ºµÇ´Â Ç÷°üÀÌ¿Ï¿äÀÎ (Endothelium-derived relaxing factor, EDRF)À» ¹ß°ßÇß°í, ÀÌ EDRF°¡ ±âüÀÎ "NO"À̸ç ÀÎü¿¡¼­ È£¸£¸óÀÌ ¾Æ´Ñ ±âü°¡ ½ÅÈ£ Àü´Þ ¹°Áú·Î ÀÛ¿ëÇÏ´Â »õ ¿ø¸®¸¦ ¹àÇô³»¾ú´Ù.

¹Â¶óµå´Â ´ÏÆ®·Î±Û¸®¼¼¸°¿¡¼­ À¯¸®µÈ NO°¡ ¼¼Æ÷Áú ³» guanylate cyclase¸¦ È°¼ºÈ­½ÃÄÑ cGMP³óµµ¸¦ Áõ°¡½ÃÅ°°í ½ÉÀå Ç÷°ü ÆòÈ°±ÙÀ» À̿ϽÃÄÑ Çù½ÉÁõ¿¡ Àû¿ëÇÒ ¼ö ÀÖ´Ù´Â »ç½ÇÀ» , ÆÛÄ¡ÄÚÆ®´Â Ç÷°ü³»ÇǼ¼Æ÷ÀÇ ±â´ÉÀÌ »ì¾Æ ÀÖ´Â °æ¿ì ¾Æ¼¼Ä¥Äݸ° µî¿¡ ÀÇÇØ EDRF°¡ »ý¼ºµÇ¸é Ç÷°ü ÆòÈ°±ÙÀÌ À̿ϵȴٴ »ç½ÇÀ», À̱׳ª·Î´Â EDRF¸¦ ÀÛµ¿½ÃÅ°´Â ¹°ÁúÀÌ Ã¼³»¿¡¼­ »ý¼ºµÇ´Â NOÀÓÀ» ¹àÇû´Ù.

NO´Â ȦÀüÀÚÀÇ ÀÚÀ¯¶óµðÄ®À» °¡Áö°í ÀÖ¾î ¹ÝÀÀ¼ºÀÌ ÀÖÀ¸¸ç ¹°¿¡ ¾à°£ ³ìÀ¸¹Ç·Î Á¶Á÷À¸·Î ºü¸£°Ô È®»êµÇ¾î ¿©·¯ °¡Áö ´Ù¾çÇÑ ¿ªÇÒÀ» ¼öÇàÇÒ ¼ö ÀÖ´Ù.

 ¡ã [±×¸² 1] Ç÷°ü³»ÇǼ¼Æ÷¿¡¼­ÀÇ NO »ý¼º°ú Ç÷°ü ÆòÈ°±Ù ÀÌ¿Ï [A]
ÀÌÈÄ À̱׳ª·Î´Â NO °¡½º¸¦ ¸¶½Ã±âº¸´Ù ¾Æ¸£±â´Ñ °æ±¸ ¼·Ã븦 ÅëÇØ Ã¼³» NO»ý¼ºÀ» µ½´Â °ÍÀÌ °Ç°­À» À¯ÁöÇÏ´Â ±æÀ̶ó´Â ³»¿ëÀÇ °­¿¬À» Çѱ¹¿¡¼­µµ µÎ Â÷·Ê ÇÑ ÀûÀÌ ÀÖ´Ù.[B]

[±×¸² 2]¿¡¼­ º¸µíÀÌ NO´Â Çص¶À» À§ÇÑ °£ÀÇ urea cycle¿¡¼­µµ »ý¼ºÀÌ µÈ´Ù. ÀÌ urea cycleÀÌ ¿øÈ°È÷ µ¹¾Æ°¡±â À§Çؼ­´Â ¾Æ¸£±â´Ñ°ú ÇÔ²² ¾Æ½ºÆĸ£Æ®»êµµ ÇÊ¿äÇÏ´Ù. ÀÌ ¾Æ½ºÆĸ£Æ®»êÀº ¿¡³ÊÁö¸¦ »ý¼ºÇÏ´Â crebsȸ·ÎÀÇ Çʼö ¹°ÁúÀ̱⵵ Çѵ¥ urea cycleÀ» ÅëÇÑ ¾Ï¸ð´Ï¾ÆÀÇ Á¦°Å, ÇǷο¡ ´ëÇÑ ÀúÇ×¼º Áõ°¡, Áö±¸·Â Áõ°¡¸¦ À§ÇØ ¾²ÀδÙ. purineÀÇ Àü±¸Ã¼·Î¼­ ÇÙ»ê ÇÕ¼º¿¡ ¾²À̱⵵ ÇÑ´Ù.

 ¡ã [±×¸² 2] urea cycle and krebs cycle [C]

[±×¸² 1]ÀÇ eNOSó·³ NO¸¦ »ý¼ºÇϱâ À§Çؼ­´Â NOS¶ó´Â È¿¼Ò°¡ ÇÊ¿äÇѵ¥ 3°¡ÁöÀÇ ¼­ºêÇüÅ°¡ ÀÖ¾î °¢±â ´Ù¸¥ ¿ªÇÒÀ» ÇÑ´Ù. eNOS(endothelial NOS)¿Í nNOS(neuronal NOS), ºÐºñ °¡´ÉÇÑ ÇüÅÂÀÇ iNOS(¸é¿ª¹ÝÀÀ¿¡ ¿¬°ü, Ä®¸ðµÑ¸° °áÇÕÀ¸·Î ¸¹Àº ¾çÀÇ NO¸¦ »ý¼ºÇÏ¿© ¸é¿ª ´ã´ç)°¡ ÀÖ´Ù. ÀÌ eNOS, nNOS, iNOS´Â óÀ½¿¡ °¢°¢ Ç÷°ü³»ÇǼ¼Æ÷, ½Å°æ¼¼Æ÷, ´ë½Ä¼¼Æ÷¿¡¼­ ¹ß°ßµÇ¾úÁö¸¸ ½ÇÁ¦·Î´Â ´Ù¾çÇÑ ¼¼Æ÷³ª Á¶Á÷¿¡ ºÐÆ÷µÇ¾î ÀÖ´Ù.[D]

¸é¿ª°è(iNOS ÀÛ¿ë)¿¡¼­´Â Ç×¾Ï ¹× Ç׹̻ý¹° ÀÛ¿ë, ½Å°æ°è(nNOS ÀÛ¿ë)¿¡¼­´Â ½Å°æÀü´Þ¹°Áú, ¼øȯ±â°è(eNOS ÀÛ¿ë)¿¡¼­´Â Ç÷°üÈ®Àå¹°Áú·Î ÀÌÇØÇÏ¸é µÇ´Âµ¥ Ç÷°üÀúÇ×(Áï, Ç÷¾Ð)À» Á¶ÀýÇÏ°í, Àν¶¸°ºÐºñ, ±âµµÀúÇ×, ¿¬µ¿¿îµ¿, ±×¸®°í Ç÷°ü»ý¼º°ú ½Å°æ°èÀÇ ¹ß»ý, ±â¾ï µî¿¡ °ü¿©ÇÑ´Ù.

[NOÀÇ ¿ªÇÒ]

Á» ´õ Á¤È®È÷ ¾à±¹¿¡¼­ ¾Æ¸£±â´ÑÀ» Åõ¿©Çϱâ À§ÇØ ÇÊ¿äÇÑ ¿Ü±¹ ¹®Çå ¸î ÆíÀ» ¼Ò°³ÇÑ´Ù.

1. Ç÷°ü³»ÇǼ¼Æ÷ÀÇ ±â´ÉÀÌ Á¤»óÀÎ °æ¿ì [E] NO »ý¼ºÀÇ À¯ÀÏÇÑ ±âÁúÀÎ ¾Æ¸£±â´Ñ ¼·Ãë·Î Ç÷°ü ½ÉÀå°èÀÇ Ç×»ó¼ºÀÌ À¯ÁöµÇ¾ú°í µ¿¹°½ÇÇè¿¡¼­ Ç÷¼ÒÆÇ°ú Ç÷¾×ÀÀ°í ½Ã½ºÅÛ¿¡ ¿µÇâÀ» ÁÖ¾ú´Ù.


2. ¾Æ¸£±â´Ñ Åõ¿©´Â[F] °ú´ÙÇÑ È°¼º»ê¼Ò ¾ïÁ¦·Î I/R injury (±¹¼ÒºóÇ÷/Àç°ü·ù¼Õ»ó)¿¹¹æ È¿°ú°¡ ÀÖ´Ù.

3. ¿îµ¿¼±¼ö¿¡°Ô Áö¼ÓÀûÀ¸·Î L-arginine-L- aspartate¸¦ Åõ¿©Çϸé Áö¹æ»ê »êÈ­¸¦ ÃËÁøÇÏ°í Á¥»êÃàÀûÀ» ÁÙÀ̸ç ÃÑ»ê¼Ò ¼Òºñ¸¦ °¨¼Ò½ÃÅ°°í ¿îµ¿ È¿À²À» ³ôÀδÙ.[G]

4. ¿îµ¿Áß ¾Æ¸£±â´Ñ °ø±ÞÀº[H] ±ÙÀ°ÀÇ Æ÷µµ´ç ÀÌ¿ëÀ» Áõ°¡½ÃÅ°°í Áö¹æ»êÀÇ »êÈ­¸¦ ÃËÁø½ÃŲ´Ù.

5. Àå±â°£ÀÇ ¾Æ¸£±â´Ñ ¼·Ãë´Â[I] Á÷°æÀÌ ÀÛÀº °ü»óµ¿¸Æ ³»ÇǼ¼Æ÷ ±â´ÉÀ» Çâ»ó½ÃŲ´Ù.

6. °í¿ë·®ÀÇ ¾Æ¸£±â´Ñ °æ±¸Åõ¿©´Â[J] ¹ß±âºÎÀü¿¡ È¿°ú°¡ ÀÖ´Ù. 60³â´ëºÎÅÍ À¯·´¿¡¼­´Â ³²¼º ºÒÀÓ, ¹ß±âºÎÀü¿¡ ´ëÇÑ ¾Æ¸£±â´Ñ °ü·Ã ¿¬±¸°¡ Áö¼ÓµÇ¾î ¿Ô´Ù.

±¹³» ¹®Çåµµ »êÈ­Áú¼Ò¸¦ Å°¿öµå·Î È®ÀÎÇغ¸¸é Á¤¸» ´Ù¾çÇÑ ¿ëµµ·Î ÀÌ¿ëµÇ´Â °ÍÀ» ¾Ë ¼ö ÀÖ´Ù. ¾Æ¸£±â´Ñ ÇÑ °¡Áö º¹¿ëÀ¸·Î 3°¡ÁöÀÇ ¿ªÇÒÀ» ÇÒ ¼ö Àֱ⠶§¹®ÀÌ´Ù.

Ãâó¿Í °¢ÁÖ
[A] page 501"; name_="Myocardial Oxygen Supply and Demand Relationship: Zipes: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine"

[B] [»ç¶÷»ç¶÷] ³ëº§ ÀÇÇлó ¹ÞÀº ·çÀ̽º À̱׳ª·Î ±³¼ö Áß¾ÓÀϺ¸ 2004.11.21

[C} NMR metabolic profiling of serum identifies amino acid disturbances in chronic fatigue syndrome Christopher W. Armstrong ¿Ü5ÀÎ, Clinica Chimica Acta 413 (2012) 1525–.1531

[D] Synthesis of Nitric Oxide¿¡¼­ ¹ßÃé http://www.reading.ac.uk/nitricoxide/intro/no/synthesis.htm

[E] L-arginine and cardiovascular system

[F] L-Arginine Treatment Alters the Kinetics of Nitric Oxide and Superoxide Release and Reduces Ischemia/Reperfusion Injury in Skeletal Muscle

[G} THE PROLONGED INTAKE OF L-ARGININE-L-ASPARTATE REDUCES BLOOD LACTATE ACCUMULATION AND OXYGEN CONSUMPTION DURING SUBMAXIMAL EXERCISE

[H] L-Arginine infusion increases glucose clearance during prolonged exercise in humans

[I} Long-term L-Arginine Supplementation Improves Small-Vessel Coronary Endothelial Function in Humans

[K] Effect of oral administration of high-dose nitric oxide donor l-arginine in men with organic erectile dysfunction: results of a double-blind, randomized, placebo-controlled study
µ¥Àϸ®ÆÊ (dailypharm@dailypharm.com) ±âÀÚÀÇ ´Ù¸¥±â»ç º¸±â
  • Àμâ
  • Ä«Ä«¿ÀÅå
  • ÆäÀ̽ººÏ
  • Æ®À§ÅÍ
  • 0
/home/dailypharm/issueData2017/
¾à±¹ ÀÏ¹Ý¾à ¸ÅÃâ¾× Top 100(06¿ù)
¼øÀ§ »óÇ°¸í Ƚ¼ö ¼ö·® ÆǸűݾ×
1 ŸÀÌ·¹³îÁ¤500mg(10Á¤) 22968 30982 96,372,090¿ø
2 ±î½ºÈ°¸í¼öÅ¥¾× 11047 67489 79,442,810¿ø
3 ÆÇÄÝ¿¡½º³»º¹¾× 9432 67868 58,407,100¿ø
4 ¾ÖÅ©³íÅ©¸² 4842 5145 57,011,601¿ø
5 ÆÇÇǸ°Å¥¾× 7836 69318 54,596,801¿ø
6 ³ë½ºÄ«³ª°Ö 20g 2442 2536 52,601,060¿ø
7 ¾Æ·Î³ª¹Î°ñµåÇÁ¸®¹Ì¾ö(120Á¤) 955 1487 50,220,400¿ø
8 º¥Æ÷º§S¿¡½ºÁ¤ 803 1377 48,577,800¿ø
9 ÄÉÅäÅéÇöó½ºÅ¸(40¸Å) 2962 3619 47,880,700¿ø
10 Ź¼¾ ¿¬Áúĸ½¶(10ĸ½¶) 11234 16847 43,822,000¿ø
11 ¸á¶óÅä´×Å©¸² 2071 2169 43,394,000¿ø
12 ºñÆÇÅÙ¿¬°í 30g 3485 6516 42,272,400¿ø
13 ÄÉÅäÅéÇöó½ºÅ¸(34¸Å) 2699 3959 38,755,600¿ø
14 ±¤µ¿°æ¿Á°í 335 10414 36,386,025¿ø
15 ÀÌ°¡Åº¿¡ÇÁĸ½¶(60ĸ½¶*3) 1211 1763 35,704,200¿ø
16 ÀÕÄ¡ÆäÀ̽ºÆ®Ä¡¾à120g 2584 3378 35,602,600¿ø
17 ÅÙÅÙÃòÁ¤(10Á¤) 11097 20982 33,804,002¿ø
18 º£³ªÄ¡¿À¿¡ÇÁ¾×75ml 7307 37090 33,104,300¿ø
19 ŸÀÌ·¹³îÁ¤500mg(30Á¤) 3213 5862 32,835,210¿ø
20 ÅÙÅÙÃòÁ¤(120Á¤) 1206 2475 31,529,700¿ø
21 ¸¶µ¥Ä«¼Ö°Ö 2852 3694 31,318,501¿ø
22 ÄÝ´ë¿ø ÄÚÇÁÅ¥½Ã·´ 6363 8122 30,793,300¿ø
23 µÑÄÚ¶ô½º-¿¡½ºÀå¿ëÁ¤(40Á¤) 1819 5349 30,305,000¿ø
24 ¾Æ·º½º´ëÇü 3810 9206 29,608,550¿ø
25 ÈĽõò¿¬°í10g 3490 3838 28,203,600¿ø
26 °Ôº¸¸°Á¤ 5193 8728 27,943,865¿ø
27 ¾ÖÅ©¸°°Ö 2237 2288 27,257,000¿ø
28 ºñ¸Æ½º¸ÞŸºñ 451 825 27,251,099¿ø
29 ±¤µ¿¿ìȲû½É¿øÇöŹ¾×50ml(õ¿¬»çÇâ) 1158 2193 27,146,100¿ø
30 Áö¸£ÅØÁ¤ 4285 5625 26,669,700¿ø
31 ÄÉÆèÇöó½ºÅ¸ 3907 10499 26,591,200¿ø
32 ¸¶µ¥Ä«¼ÖÄɾ°í10g 3546 3873 25,903,300¿ø
33 ÀÕÄ¡ÆäÀ̽ºÆ®ÇÇÅæÄ¡µå150g 1546 1887 25,835,802¿ø
34 µ¿¾ÆD-ÆÇÅ׳°í 2396 2575 25,490,770¿ø
35 ÈĽõò¿¬°í5g 4343 4648 24,733,400¿ø
36 ºñ¸Æ½ºÁ¦Æ®Á¤ 270 464 24,445,000¿ø
37 ÀÌÁö¿£6À̺ê(30ĸ½¶) 2784 3585 23,929,700¿ø
38 ¾Æ·Î³ª¹Î°ñµå(100Á¤) 696 1355 23,719,800¿ø
39 ¿ÀÅ¥½Ã½ºÁ¡¾È¾×0.5ml*60°³ 1243 1408 22,833,200¿ø
40 ±¤µ¿¿ìȲû½É¿øȯ(»çÇâ) 260 1753 22,626,500¿ø
41 ¸¶±×ºñ½ºÇǵå¾× 1944 10651 22,357,300¿ø
42 ¸Ó½Ã·ÐÁ¤ 2006 2404 21,841,500¿ø
43 ÇÁ·»Áî¾ÆÀ̵å·ÓÁ¡¾È¾×ÄðÇÏÀÌ ¾÷14ml 3311 3595 20,899,091¿ø
44 ±¤µ¿¿ìȲû½É¿øÇöŹ¾×50ml(¿µ¹¦Çâ) 1387 3174 20,810,500¿ø
45 Å׶óÇ÷ç Äݵå&ÄÚÇÁ ³ªÀÌÆ® 1532 1702 20,627,200¿ø
46 ³ë½ºÄ«³ª°Ö10g 1641 1663 20,617,000¿ø
47 Àλ絹Ç÷¯½º(100Á¤) 602 1713 20,405,000¿ø
48 ¼¾½Ã¾ÆÁ¤(120Á¤) 352 599 20,143,000¿ø
49 ¸¶±×ºñ¸Æ½º¿¬Áúĸ½¶ 398 717 20,003,500¿ø
50 ÇÁ·»Áî¾ÆÀ̵å·ÓÁ¡¾È¾×Äð ¾÷14ml 3094 3274 19,111,000¿ø
51 ¹éÃʽ÷´Ç÷¯½º 2845 3622 18,790,001¿ø
52 ¸¶µ¥Ä«¼ÖÄɾ°í 6g 3664 3938 18,336,400¿ø
53 ¾Æ·º½ºÁßÇü 3549 5809 18,066,750¿ø
54 ¶ó¶ó¿Ã¶ó¾× 20mL 1462 5671 18,011,800¿ø
55 ¸¶±×ºñ½ºÇÇµå ´õºí¾×¼Ç 987 5551 17,993,501¿ø
56 ºñ¸Æ½º¸ÞŸÁ¤(60Á¤*2) 347 642 17,949,505¿ø
57 ¸ðµåÄÝ¿¡½º 4386 6523 17,843,301¿ø
58 ¼¾½Ã¾Æ(180Á¤) 233 419 17,674,500¿ø
59 ¿ëÇ¥¿ìȲû½É¿ø¾× 50ml 1567 3953 17,405,011¿ø
60 ÄÚ¾ØÄ𠳪Àß½ºÇÁ·¹ÀÌ 1476 1745 17,221,900¿ø
61 ÀÌÁö¿£6À̺꿬Áúĸ½¶ 4722 6023 16,361,400¿ø
62 ´ë¿õ¿ì·ç»ç¿¬Áúĸ½¶(120ĸ½¶) 408 663 16,318,300¿ø
63 Àλ絹Ç÷¯½º(270Á¤) 208 1018 16,226,200¿ø
64 ´ºº£ÀÎ¾× 628 6299 16,219,800¿ø
65 ŸÀÌ·¹³î8½Ã°£À̾˼­¹æÁ¤ 3824 5566 15,998,800¿ø
66 ÇÁ·»Áî¾ÆÀ̵å·ÓÁ¡¾È¾×¼ø ¾÷14ml 2503 2741 15,979,100¿ø
67 ¿ÀÆ®¸®ºó¸àÅç0.1%ºÐ¹«Á¦ 1217 1612 15,839,300¿ø
68 À¯ÇѺñŸ¹ÎCÁ¤1000mg 848 2739 15,829,453¿ø
69 ´ÏÄÚ·¹Æ®²­ 2mg (Äð¹ÎÆ®Çâ) 695 1597 15,634,000¿ø
70 Ź¼¾·¹À̵ð 3293 4098 15,442,000¿ø
71 Ä«¸®ÅäÆ÷ÅÙ¿¬Áúĸ½¶(60ĸ½¶) 350 427 15,398,990¿ø
72 Ŭ¸®¾îƾ 1258 1303 15,391,300¿ø
73 Ä¡¼¾Ä¸½¶(120ĸ½¶) 310 435 15,376,600¿ø
74 ¾ÈƼǪ¶ó¹ÎÄðīŸÇö󽺸¶(5¸Å) 2967 5050 15,340,000¿ø
75 ¸®¾ÈÁ¡¾È¾× 766 858 15,166,600¿ø
76 ¾ÈƼǪ¶ó¹Î ´õºíÆÄ¿ö ´ëÇü 1946 4290 15,072,975¿ø
77 ÄÝ´ë¿ø ÄݵåÅ¥½Ã·´ 3225 4117 15,054,900¿ø
78 Ä¡¼¾Ä¸½¶(60ĸ½¶) 517 1468 14,904,500¿ø
79 èÇÁ½Ã·´ 2505 2891 14,890,001¿ø
80 ½ºÆ¼¸ð¸°¿¡½ºÅ©¸²10g 1663 1740 14,819,400¿ø
81 ¿ëÇ¥¿ìȲû½É¿ø¾×50ml(õ¿¬»çÇ⺯¹æ) 754 1469 14,736,201¿ø
82 ±¤µ¿¿øÅÁ 3844 15541 14,612,906¿ø
83 Ź¼¾ ¿¬Áúĸ½¶(30ĸ½¶) 1654 2600 14,524,000¿ø
84 µå¸®Å¬·Î¾×20ml(½ÅÇü) 989 1047 14,423,700¿ø
85 Á¶¾ÆÆË(10¸Å) 1841 2917 14,419,800¿ø
86 ¾ÆÀ̹̻ê 217 12927 13,659,500¿ø
87 ÀÕÄ¡ ÇÁ·ÎÆú¸®½º 804 930 13,656,001¿ø
88 ÄÝ´ë¿øÅ°Áî³ëÁî¿¡½º½Ã·´ 2950 3824 13,651,400¿ø
89 ÄÝ´ë¿ø ³ëÁîÅ¥¿¡½º½Ã·´ 2839 3532 13,560,000¿ø
90 µðÆæÄðÇöó½ºÅ¸(10¸Å) 2027 5014 13,556,200¿ø
91 ¸Æ½ÃºÎÅ°Áî½Ã·´ 2500 3157 13,409,100¿ø
92 ³ë½º¿§¼¾½º¾× 1308 1358 13,269,500¿ø
93 Å׶óÇÃ·ç ³ªÀÌƮŸÀÓ 1329 1672 13,240,176¿ø
94 ¾ÈƼǪ¶ó¹Î ´õºíÆÄ¿ö ÁßÇü 2165 5357 13,237,100¿ø
95 °ÖÆ÷½º¿¤ 1699 2188 13,128,500¿ø
96 ÄÚ¸ÞÅ°³ªÄ¸½¶ 2317 2868 12,994,648¿ø
97 ÈѽºÅ»Ç÷¯½º 2993 4584 12,941,400¿ø
98 Å©¸°Å¬¸ê±Õ»ý¸®½Ä¿°¼ö20ml*20¾ÚÇà 1168 2186 12,751,120¿ø
99 Àλ絹(100Á¤) 417 529 12,698,400¿ø
100 ºñÆÇÅÙ¿¬°í 100g 476 505 12,666,100¿ø
Àüüº¸±â



ÀÎÅͳݽŹ®µî·Ï¹øÈ£: ¼­¿ï¾Æ00048 | µî·ÏÀÏÀÚ 2005.09.09 | ¹ßÇàÀÏÀÚ 2005.09.09 | ¹ßÇàÀÎ : ÀÌÁ¤¼® | ÆíÁýÀÎ : °¡ÀÎÈ£
¹ßÇàÁÖ¼Ò: ¼­¿ï½Ã ¼ÛÆı¸ ¹ý¿ø·Î 128 ¹®Á¤ SK V1 GL ¸ÞÆ®·Î½ÃƼ Aµ¿ 401È£
ÀüÈ­ : 02-3473-0833 |Æѽº : 02-3474-0169 | û¼Ò³âº¸È£Á¤Ã¥(Ã¥ÀÓÀÚ °­½Å±¹)
Contact dailypharm@dailypharm.com for more information
µ¥Àϸ®ÆÊÀÇ ¸ðµç ÄÜÅÙÃ÷(±â»ç)¸¦ ¹«´Ü »ç¿ëÇÏ´Â °ÍÀº ÀúÀ۱ǹý¿¡ ÀúÃ˵Ǹç, ¹ýÀû Á¦À縦 ¹ÞÀ» ¼ö ÀÖ½À´Ï´Ù.